Antinuclear autoantibodies in chronic schizophrenia

Area of Science:

• Immunology
• Psychiatry
• Autoimmunity

Background:

• Antinuclear autoantibodies (ANA) are associated with various autoimmune diseases.
• The role of autoimmunity in the pathophysiology of schizophrenia is an area of ongoing investigation.
• Previous research has yielded conflicting results regarding ANA prevalence in schizophrenia.

Purpose of the Study:

• To investigate the frequency of ANA, specifically antinative DNA and histone-reactive ANA, in different subgroups of chronic schizophrenic patients.
• To compare ANA prevalence in schizophrenic patients with that of healthy controls.
• To determine if drug treatment influences ANA presence in schizophrenia.

Main Methods:

• Assessed ANA, antinative DNA, and histone-reactive ANA in 85 chronic schizophrenic patients (haloperidol-treated, drug-free, neuroleptic-naive) and 37 healthy controls.
• Compared autoantibody titers between patient groups and controls.
• Analyzed data considering treatment status, sex, and age.

Main Results:

• A significantly higher frequency of positive ANA was observed in chronic schizophrenic patients (approx. 20%) compared to healthy controls (approx. 5%).
• This increased ANA prevalence was independent of medication status, sex, or age.
• No antinative ANA or histone-reactive ANA were detected in any participant group.

Conclusions:

• Chronic schizophrenia is associated with a higher prevalence of ANA, suggesting a potential autoimmune component.
• The observed ANA positivity is not linked to neuroleptic treatment, drug-free status, or neuroleptic-naive status.
• Further research is required to identify specific ANA profiles in ANA-positive schizophrenic patients and elucidate their clinical significance.